Chinese General Practice ›› 2022, Vol. 25 ›› Issue (18): 2194-2200.DOI: 10.12114/j.issn.1007-9572.2022.02.009
Special Issue: 骨质疏松最新文章合集; 老年人群健康最新文章合集; 骨健康最新文章合集; 老年问题最新文章合集
• Article·Osteoporosis Study • Previous Articles Next Articles
Received:
2021-11-18
Revised:
2022-01-05
Published:
2022-06-20
Online:
2022-01-27
Contact:
Yan LI
About author:
通讯作者:
李燕
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.02.009
变量 | 非骨质疏松症组(n=176) | 骨质疏松症组(n=126) | χ2(t)值 | P值 | 变量 | 非骨质疏松症组(n=176) | 骨质疏松症组(n=126) | χ2(t)值 | P值 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
性别〔n(%)〕 | 11.189 | 0.001 | 抑郁情况〔n(%)〕 | 5.544 | 0.019 | ||||||
男 | 115(65.3) | 58(46.0) | 无 | 81(46.0) | 41(32.5) | ||||||
女 | 61(34.7) | 68(54.0) | 有 | 95(54.0) | 85(67.5) | ||||||
年龄〔n(%)〕 | 8.619 | 0.013 | 焦虑情况〔n(%)〕 | 0.005 | 0.945 | ||||||
60~<75岁 | 82(46.6) | 38(30.2) | 无 | 156(88.6) | 112(88.9) | ||||||
75~<85岁 | 51(29.0) | 44(34.9) | 有 | 20(11.4) | 14(11.1) | ||||||
≥85岁 | 43(24.4) | 44(34.9) | 日常生活能力〔n(%)〕 | 10.710 | 0.013 | ||||||
身高( | 162.0±7.7 | 159.3±8.8 | 2.783a | 0.006 | 日常生活能力良好 | 77(43.8) | 37(29.3) | ||||
体质量( | 61.8±10.5 | 58.4±10.5 | 2.767a | 0.006 | 轻度功能障碍 | 40(22.7) | 49(38.9) | ||||
BMI( | 23.5±3.4 | 23.2±6.1 | 0.527a | 0.599 | 中度功能障碍 | 29(16.5) | 21(16.7) | ||||
食物或药物过敏史〔n(%)〕 | 39(22.2) | 32(25.4) | 0.428 | 0.513 | 重度功能障碍 | 30(17.0) | 19(15.1) | ||||
语言功能异常〔n(%)〕 | 14(8.0) | 8(6.3) | 0.280 | 0.597 | 睡眠情况〔n(%)〕 | 8.619 | 0.013 | ||||
视力下降〔n(%)〕 | 121(68.8) | 87(69.0) | 0.003 | 0.956 | 睡眠良好 | 87(49.4) | 43(34.1) | ||||
听力下降〔n(%)〕 | 97(55.1) | 78(61.9) | 1.390 | 0.238 | 潜在失眠 | 46(26.2) | 35(27.8) | ||||
皮肤异常〔n(%)〕 | 10(5.7) | 6(4.8) | 0.124 | 0.725 | 失眠 | 43(24.4) | 48(38.1) | ||||
离婚或丧偶〔n(%)〕 | 34(19.3) | 36(28.6) | 4.153 | 0.125 | 近1年跌倒情况〔n(%)〕 | 3.343 | 0.067 | ||||
饮食习惯〔n(%)〕 | 5.861 | 0.015 | 无 | 158(89.8) | 104(82.5) | ||||||
清淡为主 | 145(82.4) | 116(92.1) | 有 | 18(10.2) | 22(17.5) | ||||||
咸腻为主 | 31(17.6) | 10(7.9) | 跌倒风险〔n(%)〕 | 6.199 | 0.045 | ||||||
需服用助眠药〔n(%)〕 | 29(16.5) | 31(24.6) | 3.046 | 0.081 | 低度风险 | 103(58.5) | 60(47.6) | ||||
当前吸烟〔n(%)〕 | 39(22.2) | 26(20.6) | 0.101 | 0.751 | 中度风险 | 32(18.2) | 38(30.2) | ||||
当前饮酒〔n(%)〕 | 27(15.3) | 20(15.9) | 0.016 | 0.900 | 重度风险 | 41(23.3) | 28(22.2) | ||||
尿失禁〔n(%)〕 | 13(7.4) | 17(13.5) | 3.060 | 0.080 | 平衡步态情况〔n(%)〕 | 3.178 | 0.204 | ||||
疼痛〔n(%)〕 | 49(28.0) | 48(38.1) | 3.418 | 0.064 | 躯体功能良好 | 86(48.9) | 49(38.9) | ||||
便秘〔n(%)〕 | 35(19.9) | 38(30.2) | 4.227 | 0.040 | 平衡障碍 | 50(28.4) | 40(31.7) | ||||
营养情况〔n(%)〕 | 7.537 | 0.023 | 有跌倒危险 | 40(22.7) | 37(29.4) | ||||||
营养良好 | 97(55.1) | 51(40.5) | 衰弱情况〔n(%)〕 | 6.203 | 0.045 | ||||||
潜在营养不良 | 60(34.1) | 51(40.5) | 无衰弱 | 83(47.2) | 43(34.1) | ||||||
营养不良 | 19(10.8) | 24(19.0) | 衰弱前期 | 41(23.3) | 43(34.1) | ||||||
认知功能〔n(%)〕 | 3.210 | 0.523 | 衰弱期 | 52(29.5) | 40(31.8) | ||||||
认知正常 | 84(47.7) | 53(42.0) | 睡眠时间( | 7.06±1.81 | 6.88±1.98 | 0.827a | 0.409 | ||||
轻度障碍 | 60(34.1) | 49(38.9) | 合并慢性疾病数量( | 6.77±3.41 | 7.88±2.77 | -3.129a | 0.002 | ||||
中度障碍 | 20(11.4) | 19(15.1) | 用药数量( | 5.86±3.51 | 6.66±2.99 | -2.071a | 0.039 | ||||
重度障碍 | 12(6.8) | 5(4.0) |
Table 1 Comparison of general data and geriatric syndromes between non-osteoporosis group and osteoporosis group
变量 | 非骨质疏松症组(n=176) | 骨质疏松症组(n=126) | χ2(t)值 | P值 | 变量 | 非骨质疏松症组(n=176) | 骨质疏松症组(n=126) | χ2(t)值 | P值 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
性别〔n(%)〕 | 11.189 | 0.001 | 抑郁情况〔n(%)〕 | 5.544 | 0.019 | ||||||
男 | 115(65.3) | 58(46.0) | 无 | 81(46.0) | 41(32.5) | ||||||
女 | 61(34.7) | 68(54.0) | 有 | 95(54.0) | 85(67.5) | ||||||
年龄〔n(%)〕 | 8.619 | 0.013 | 焦虑情况〔n(%)〕 | 0.005 | 0.945 | ||||||
60~<75岁 | 82(46.6) | 38(30.2) | 无 | 156(88.6) | 112(88.9) | ||||||
75~<85岁 | 51(29.0) | 44(34.9) | 有 | 20(11.4) | 14(11.1) | ||||||
≥85岁 | 43(24.4) | 44(34.9) | 日常生活能力〔n(%)〕 | 10.710 | 0.013 | ||||||
身高( | 162.0±7.7 | 159.3±8.8 | 2.783a | 0.006 | 日常生活能力良好 | 77(43.8) | 37(29.3) | ||||
体质量( | 61.8±10.5 | 58.4±10.5 | 2.767a | 0.006 | 轻度功能障碍 | 40(22.7) | 49(38.9) | ||||
BMI( | 23.5±3.4 | 23.2±6.1 | 0.527a | 0.599 | 中度功能障碍 | 29(16.5) | 21(16.7) | ||||
食物或药物过敏史〔n(%)〕 | 39(22.2) | 32(25.4) | 0.428 | 0.513 | 重度功能障碍 | 30(17.0) | 19(15.1) | ||||
语言功能异常〔n(%)〕 | 14(8.0) | 8(6.3) | 0.280 | 0.597 | 睡眠情况〔n(%)〕 | 8.619 | 0.013 | ||||
视力下降〔n(%)〕 | 121(68.8) | 87(69.0) | 0.003 | 0.956 | 睡眠良好 | 87(49.4) | 43(34.1) | ||||
听力下降〔n(%)〕 | 97(55.1) | 78(61.9) | 1.390 | 0.238 | 潜在失眠 | 46(26.2) | 35(27.8) | ||||
皮肤异常〔n(%)〕 | 10(5.7) | 6(4.8) | 0.124 | 0.725 | 失眠 | 43(24.4) | 48(38.1) | ||||
离婚或丧偶〔n(%)〕 | 34(19.3) | 36(28.6) | 4.153 | 0.125 | 近1年跌倒情况〔n(%)〕 | 3.343 | 0.067 | ||||
饮食习惯〔n(%)〕 | 5.861 | 0.015 | 无 | 158(89.8) | 104(82.5) | ||||||
清淡为主 | 145(82.4) | 116(92.1) | 有 | 18(10.2) | 22(17.5) | ||||||
咸腻为主 | 31(17.6) | 10(7.9) | 跌倒风险〔n(%)〕 | 6.199 | 0.045 | ||||||
需服用助眠药〔n(%)〕 | 29(16.5) | 31(24.6) | 3.046 | 0.081 | 低度风险 | 103(58.5) | 60(47.6) | ||||
当前吸烟〔n(%)〕 | 39(22.2) | 26(20.6) | 0.101 | 0.751 | 中度风险 | 32(18.2) | 38(30.2) | ||||
当前饮酒〔n(%)〕 | 27(15.3) | 20(15.9) | 0.016 | 0.900 | 重度风险 | 41(23.3) | 28(22.2) | ||||
尿失禁〔n(%)〕 | 13(7.4) | 17(13.5) | 3.060 | 0.080 | 平衡步态情况〔n(%)〕 | 3.178 | 0.204 | ||||
疼痛〔n(%)〕 | 49(28.0) | 48(38.1) | 3.418 | 0.064 | 躯体功能良好 | 86(48.9) | 49(38.9) | ||||
便秘〔n(%)〕 | 35(19.9) | 38(30.2) | 4.227 | 0.040 | 平衡障碍 | 50(28.4) | 40(31.7) | ||||
营养情况〔n(%)〕 | 7.537 | 0.023 | 有跌倒危险 | 40(22.7) | 37(29.4) | ||||||
营养良好 | 97(55.1) | 51(40.5) | 衰弱情况〔n(%)〕 | 6.203 | 0.045 | ||||||
潜在营养不良 | 60(34.1) | 51(40.5) | 无衰弱 | 83(47.2) | 43(34.1) | ||||||
营养不良 | 19(10.8) | 24(19.0) | 衰弱前期 | 41(23.3) | 43(34.1) | ||||||
认知功能〔n(%)〕 | 3.210 | 0.523 | 衰弱期 | 52(29.5) | 40(31.8) | ||||||
认知正常 | 84(47.7) | 53(42.0) | 睡眠时间( | 7.06±1.81 | 6.88±1.98 | 0.827a | 0.409 | ||||
轻度障碍 | 60(34.1) | 49(38.9) | 合并慢性疾病数量( | 6.77±3.41 | 7.88±2.77 | -3.129a | 0.002 | ||||
中度障碍 | 20(11.4) | 19(15.1) | 用药数量( | 5.86±3.51 | 6.66±2.99 | -2.071a | 0.039 | ||||
重度障碍 | 12(6.8) | 5(4.0) |
组别 | 例数 | WBC( | NEUT〔M(P25,P75),×109/L〕 | RBC( | Hb ( | PLT ( | CRP〔M(P25,P75),mg/L〕 | AST〔M(P25,P75),U/L〕 |
---|---|---|---|---|---|---|---|---|
非骨质疏松症组 | 176 | 7.02±3.00 | 4.20(3.04,5.35) | 4.39±0.79 | 133.88±25.52 | 211.38±85.86 | 6.09(1.18,31.22) | 20.00(15.00,26.00) |
骨质疏松症组 | 126 | 6.21±2.09 | 3.63(2.72,4.65) | 4.20±0.68 | 127.02±19.68 | 200.17±66.76 | 2.90(0.80,13.91) | 19.00(15.00,24.50) |
Z(t)值 | 2.761a | -2.576 | 2.229a | 2.638a | 1.224a | -2.444 | -0.983 | |
P值 | 0.006 | 0.010 | 0.027 | 0.009 | 0.222 | 0.015 | 0.325 | |
组别 | ALT 〔M(P25,P75),U/L〕 | TG〔M(P25,P75),mmol/L〕 | TP ( | ALB ( | TC ( | HDL ( | LDL ( | Cr〔M(P25,P75),μmol/L〕 |
非骨质疏松症组 | 15.00(10.00,22.00) | 1.15(0.78,1.77) | 63.68±6.80 | 35.94±5.39 | 4.07±1.09 | 1.04±0.34 | 2.45±0.84 | 76.00(60.00,93.00) |
骨质疏松症组 | 13.00(10.00,20.00) | 1.23(0.87,1.90) | 65.41±9.47 | 36.41±4.83 | 4.19±1.06 | 1.10±0.33 | 2.45±0.88 | 77.50(63.00,99.00) |
Z(t)值 | -1.426 | -0.982 | -1.855a | -0.779a | -0.966a | -1.550a | -0.043a | -1.176 |
P值 | 0.154 | 0.326 | 0.065 | 0.437 | 0.335 | 0.122 | 0.966 | 0.240 |
组别 | BUN〔M(P25,P75),μmol/L〕 | SUA ( | T4 ( | T3〔M(P25,P75),nmol/L〕 | TSH〔M(P25,P75),mU/L〕 | 空腹血糖〔M(P25,P75),mmol/L〕 | HbA1c〔M(P25,P75),%〕 | |
非骨质疏松症组 | 6.20(4.80,8.30) | 342.36±116.41 | 80.14±19.64 | 1.09(0.82,1.43) | 2.58(1.45,4.48) | 5.40(4.60,6.10) | 6.30(5.73,6.60) | |
骨质疏松症组 | 6.45(5.30,9.10) | 357.59±86.57 | 77.82±17.03 | 1.03(0.80,1.40) | 2.70(1.68,4.48) | 4.90(4.40,6.10) | 6.19(5.56,6.87) | |
Z(t)值 | -1.228 | 2.021a | 1.068a | -0.862 | -0.483 | -1.730 | -0.582 | |
P值 | 0.220 | 0.044 | 0.286 | 0.389 | 0.629 | 0.084 | 0.561 | |
组别 | 果糖胺〔M(P25,P75),μmol/L〕 | 铁蛋白〔M(P25,P75),μg/L〕 | 维生素B12 〔M(P25,P75),pmol/L〕 | 叶酸〔M(P25,P75),nmol/L〕 | 睾酮〔M(P25,P75),nmol/L〕 | 雌二醇( | Hcy〔M(P25,P75),μmol/L〕 | |
非骨质疏松症组 | 1.55(1.38,1.58) | 301.11(133.35,430.14) | 348.00(244.00,490.92) | 15.20(10.30,20.90) | 7.39(0.67,13.35) | 116.52±53.76 | 17.60(13.70,20.10) | |
骨质疏松症组 | 1.56(1.41,1.67) | 232.81(110.94,341.75) | 424.50(261.00,629.75) | 16.80(10.00,28.00) | 1.42(0.45,10.96) | 117.72±60.64 | 18.51(15.30,21.80) | |
Z(t)值 | -1.661 | -2.047 | -1.406 | -1.167 | -2.604 | -0.180a | -2.017 | |
P值 | 0.097 | 0.041 | 0.160 | 0.243 | 0.009 | 0.857 | 0.044 | |
组别 | FINS〔M(P25,P75),U/L〕 | TNF〔M(P25,P75),ng/L〕 | IL-10〔M(P25,P75),ng/L〕 | IL-6〔M(P25,P75),ng/L〕 | IL-12P70〔M(P25,P75),ng/L〕 | IL-1β〔M(P25,P75),ng/L〕 | IL-8〔M(P25,P75),ng/L〕 | |
非骨质疏松症组 | 7.31(4.02,9.06) | 6.21(4.27,10.47) | 4.66(3.55,6.16) | 18.37(7.45,27.14) | 5.56(3.66,6.46) | 4.93(3.64,8.01) | 25.89(12.18,59.39) | |
骨质疏松症组 | 6.76(4.74,8.61) | 7.59(5.06,11.47) | 4.58(3.68,6.14) | 13.79(6.70,27.14) | 5.33(4.53,6.46) | 5.20(3.45,8.01) | 23.09(13.68,59.39) | |
Z(t)值 | -0.229 | -2.285 | -0.321 | -1.971 | -0.086 | -0.156 | -0.367 | |
P值 | 0.819 | 0.022 | 0.748 | 0.049 | 0.932 | 0.876 | 0.714 |
Table 2 Comparison of serum biomarkers between non-osteoporosis group and osteoporosis group
组别 | 例数 | WBC( | NEUT〔M(P25,P75),×109/L〕 | RBC( | Hb ( | PLT ( | CRP〔M(P25,P75),mg/L〕 | AST〔M(P25,P75),U/L〕 |
---|---|---|---|---|---|---|---|---|
非骨质疏松症组 | 176 | 7.02±3.00 | 4.20(3.04,5.35) | 4.39±0.79 | 133.88±25.52 | 211.38±85.86 | 6.09(1.18,31.22) | 20.00(15.00,26.00) |
骨质疏松症组 | 126 | 6.21±2.09 | 3.63(2.72,4.65) | 4.20±0.68 | 127.02±19.68 | 200.17±66.76 | 2.90(0.80,13.91) | 19.00(15.00,24.50) |
Z(t)值 | 2.761a | -2.576 | 2.229a | 2.638a | 1.224a | -2.444 | -0.983 | |
P值 | 0.006 | 0.010 | 0.027 | 0.009 | 0.222 | 0.015 | 0.325 | |
组别 | ALT 〔M(P25,P75),U/L〕 | TG〔M(P25,P75),mmol/L〕 | TP ( | ALB ( | TC ( | HDL ( | LDL ( | Cr〔M(P25,P75),μmol/L〕 |
非骨质疏松症组 | 15.00(10.00,22.00) | 1.15(0.78,1.77) | 63.68±6.80 | 35.94±5.39 | 4.07±1.09 | 1.04±0.34 | 2.45±0.84 | 76.00(60.00,93.00) |
骨质疏松症组 | 13.00(10.00,20.00) | 1.23(0.87,1.90) | 65.41±9.47 | 36.41±4.83 | 4.19±1.06 | 1.10±0.33 | 2.45±0.88 | 77.50(63.00,99.00) |
Z(t)值 | -1.426 | -0.982 | -1.855a | -0.779a | -0.966a | -1.550a | -0.043a | -1.176 |
P值 | 0.154 | 0.326 | 0.065 | 0.437 | 0.335 | 0.122 | 0.966 | 0.240 |
组别 | BUN〔M(P25,P75),μmol/L〕 | SUA ( | T4 ( | T3〔M(P25,P75),nmol/L〕 | TSH〔M(P25,P75),mU/L〕 | 空腹血糖〔M(P25,P75),mmol/L〕 | HbA1c〔M(P25,P75),%〕 | |
非骨质疏松症组 | 6.20(4.80,8.30) | 342.36±116.41 | 80.14±19.64 | 1.09(0.82,1.43) | 2.58(1.45,4.48) | 5.40(4.60,6.10) | 6.30(5.73,6.60) | |
骨质疏松症组 | 6.45(5.30,9.10) | 357.59±86.57 | 77.82±17.03 | 1.03(0.80,1.40) | 2.70(1.68,4.48) | 4.90(4.40,6.10) | 6.19(5.56,6.87) | |
Z(t)值 | -1.228 | 2.021a | 1.068a | -0.862 | -0.483 | -1.730 | -0.582 | |
P值 | 0.220 | 0.044 | 0.286 | 0.389 | 0.629 | 0.084 | 0.561 | |
组别 | 果糖胺〔M(P25,P75),μmol/L〕 | 铁蛋白〔M(P25,P75),μg/L〕 | 维生素B12 〔M(P25,P75),pmol/L〕 | 叶酸〔M(P25,P75),nmol/L〕 | 睾酮〔M(P25,P75),nmol/L〕 | 雌二醇( | Hcy〔M(P25,P75),μmol/L〕 | |
非骨质疏松症组 | 1.55(1.38,1.58) | 301.11(133.35,430.14) | 348.00(244.00,490.92) | 15.20(10.30,20.90) | 7.39(0.67,13.35) | 116.52±53.76 | 17.60(13.70,20.10) | |
骨质疏松症组 | 1.56(1.41,1.67) | 232.81(110.94,341.75) | 424.50(261.00,629.75) | 16.80(10.00,28.00) | 1.42(0.45,10.96) | 117.72±60.64 | 18.51(15.30,21.80) | |
Z(t)值 | -1.661 | -2.047 | -1.406 | -1.167 | -2.604 | -0.180a | -2.017 | |
P值 | 0.097 | 0.041 | 0.160 | 0.243 | 0.009 | 0.857 | 0.044 | |
组别 | FINS〔M(P25,P75),U/L〕 | TNF〔M(P25,P75),ng/L〕 | IL-10〔M(P25,P75),ng/L〕 | IL-6〔M(P25,P75),ng/L〕 | IL-12P70〔M(P25,P75),ng/L〕 | IL-1β〔M(P25,P75),ng/L〕 | IL-8〔M(P25,P75),ng/L〕 | |
非骨质疏松症组 | 7.31(4.02,9.06) | 6.21(4.27,10.47) | 4.66(3.55,6.16) | 18.37(7.45,27.14) | 5.56(3.66,6.46) | 4.93(3.64,8.01) | 25.89(12.18,59.39) | |
骨质疏松症组 | 6.76(4.74,8.61) | 7.59(5.06,11.47) | 4.58(3.68,6.14) | 13.79(6.70,27.14) | 5.33(4.53,6.46) | 5.20(3.45,8.01) | 23.09(13.68,59.39) | |
Z(t)值 | -0.229 | -2.285 | -0.321 | -1.971 | -0.086 | -0.156 | -0.367 | |
P值 | 0.819 | 0.022 | 0.748 | 0.049 | 0.932 | 0.876 | 0.714 |
变量 | β | SE | Wald χ2值 | P值 | OR(95%CI) | |
---|---|---|---|---|---|---|
睡眠情况 | — | — | 4.920 | 0.085 | — | |
潜在失眠 | 0.503 | 0.360 | 1.952 | 0.162 | 1.654(0.817,3.350) | |
失眠 | 0.779 | 0.359 | 4.726 | 0.030 | 2.180(1.080,4.443) | |
合并慢性疾病数量 | 0.201 | 0.053 | 14.150 | <0.001 | 1.223(1.101,1.358) | |
SUA | -0.004 | 0.001 | 6.415 | 0.011 | 0.996(0.993,0.999) | |
Hcy | 0.042 | 0.021 | 3.908 | 0.048 | 1.043(1.000,1.088) |
Table 3 Binary Logistic regression analysis of associated factors of osteoporosis in elderly patients with stable chronic conditions
变量 | β | SE | Wald χ2值 | P值 | OR(95%CI) | |
---|---|---|---|---|---|---|
睡眠情况 | — | — | 4.920 | 0.085 | — | |
潜在失眠 | 0.503 | 0.360 | 1.952 | 0.162 | 1.654(0.817,3.350) | |
失眠 | 0.779 | 0.359 | 4.726 | 0.030 | 2.180(1.080,4.443) | |
合并慢性疾病数量 | 0.201 | 0.053 | 14.150 | <0.001 | 1.223(1.101,1.358) | |
SUA | -0.004 | 0.001 | 6.415 | 0.011 | 0.996(0.993,0.999) | |
Hcy | 0.042 | 0.021 | 3.908 | 0.048 | 1.043(1.000,1.088) |
[1] |
中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊治指南(2011年)[J]. 中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. DOI:10.3969/j.issn.1674-2591.2011.01.002.
|
[2] |
戴靖榕,李婕,何旭,等. 慢性疾病稳定期老年患者25-羟维生素D及白介素6与衰弱的相关性研究[J]. 中国全科医学,2021,24(36):4599-4606. DOI:10.12114/j.issn.1007-9572.2021.02.037.
|
[3] |
刘宇,刘敏,沈冲,等. 江苏省句容市农村地区60岁以上老年人骨质疏松流行情况及影响因素研究[J]. 实用老年医学,2020,34(6):580-584. DOI:10.3969/j.issn.1003-9198.2020.06.017.
|
[4] |
陈林,程军,李波,等. 渝东北地区老年人骨质疏松流行病学调查[J]. 中国骨质疏松杂志,2016,22(8):1050-1052. DOI:10.3969/j.issn.1006-7108.2016.08.025.
|
[5] |
|
[6] |
吴玉怀,刘建平,赵丽娟. 血尿酸与骨质疏松性骨折的相关性[J]. 中国骨质疏松杂志,2020,26(6):808-812. DOI:10.3969/j.issn.1006-7108.2020.06.004.
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
史亮亮,张国良,邹乐,等. 老年高血压病合并骨质疏松症患者血清Hcy水平与骨密度及骨代谢指标的相关性分析[J]. 中国骨与关节损伤杂志,2020,35(9):924-927. DOI:10.7531/j.issn.1672-9935.2020.09.008.
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] | |
[21] |
|
[22] |
甘丽,幸宇,陈晓丽,等. 慢性睡眠不足诱导小鼠大脑和肝脏氧化应激和炎症反应[J]. 重庆医科大学学报,2018,43(6):836-842. DOI:10.13406/j.cnki.cyxb.001724.
|
[23] |
|
[24] |
|
[25] |
|
[26] |
姚娜,李鹏程,耿春梅,等. TNF-α介导绝经后骨质疏松症发病机制的研究进展[J]. 中国骨质疏松杂志,2021,27(3):454-458. DOI:10.3969/j.issn.1006-7108.2021.03.029.
|
[27] | |
[28] |
唐杨琛,顾朋颖,靳松,等. 80岁以上老年人多重用药的临床观察[J]. 中国临床保健杂志,2018,21(2):156-159. DOI:10.3969/J.issn.1672-6790.2018.02.004.
|
[29] |
|
[30] |
张倩,蔡文玮,王光辉. 上海市社区医院70岁以上老年人骨质疏松症流行现状调查及影响因素分析[J]. 老年医学与保健,2019,25(4):464-467. DOI:10.3969/j.issn.1008-8296.2019.04.011.
|
[1] | FENG Xiaoyu, LI Wanling, LYU Siman, NI Cuiping, WANG Haocheng, LIU Yu. International Research Status and Hot Spot Analysis of InterRAI HC Based on Bibliometrics [J]. Chinese General Practice, 2023, 26(34): 4351-4358. |
[2] | GU Hanxin, LIU Yang, LIU Yuanli. Falls Prevention Intervention for Community-dwelling Older Adults from the Perspective of Policy Tools: an International Comparative Study [J]. Chinese General Practice, 2023, 26(34): 4231-4238. |
[3] | LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307. |
[4] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[5] | YU Xinyan, ZHAO Jun, ZHAO Xiaoye, JIANG Qingru, CHEN Yatian, WANG Yan, ZHANG Haicheng. Application of Mobile Smart Healthcare in the Prevention and Control of Cardiovascular Diseases in Elderly Patients with Chronic Diseases in Primary Care [J]. Chinese General Practice, 2023, 26(33): 4167-4172. |
[6] | XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109. |
[7] | ZHANG Shuai, LI Qin, LI Dongfeng, XIAO Jinping, LI Yunpeng. A Prospective Cohort Study of Solid Fuels Use and Risk of Hypertension in Chinese Older Adults [J]. Chinese General Practice, 2023, 26(32): 4001-4006. |
[8] | JIAN Qiufeng, XU Ronghua, YAO Qian, ZHOU Yuanyuan. A Meta-analysis of the Prevalence and Influencing Factors of Post-stroke Cognitive Impairment in Chinese Elderly Patients [J]. Chinese General Practice, 2023, 26(32): 4070-4079. |
[9] | CHEN Xi, ZHANG Juan, LI Lin, ZHANG Jiaqi, WU Yaoli, GUO Hui, WANG Chaoqun. Association between Physical Activity and Risk of All-cause Mortality in Middle-aged and Elderly People in China: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(31): 3890-3895. |
[10] | ZHANG Peng, GAO Ying, YANG Hongxi, WAN Chunxiao. Association between Serum Uric Acid Level and the Risk of Chronic Kidney Disease among the Elderly in Longevity Areas of China [J]. Chinese General Practice, 2023, 26(31): 3884-3889. |
[11] | DUAN Yanqin, PENG Ying, LIU Shenglan, LIU Haijiao, YANG Huiqiong, HU Haiqing. Prevalence and Associated Factors of Potentially Inappropriate Medication among Elderly Outpatients [J]. Chinese General Practice, 2023, 26(31): 3902-3907. |
[12] | HE Jingyi, WANG Fang, SHUI Xiaoling, LI Ling, LIANG Qian. Efficacy of Non-pharmacological Interventions to Improve Perimenopausal Insomnia Symptoms: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(31): 3963-3974. |
[13] | ZHANG Ming, XU Jing, SUN Zhenhua, ZHAO Wenhao, MA Yingqian, ZHANG Jianqiao, SHEN Haiping. Improvement of Nutritional Status of Elderly Patients with Severe Obstruction Esophageal Carcinoma by Image-guided Photodynamic Therapy [J]. Chinese General Practice, 2023, 26(30): 3780-3784. |
[14] | ZHU Lin, GUO Yankui, GAO Chen, CHEN Xuezhi, WANG Fashuai. Efficacy of Western Medicine, Chinese Patent Medicine and Their Combination on Post-stroke Insomnia: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3823-3832. |
[15] | PAN Ye, LIU Zhihui, HU Qianqian, WANG Liuyi. Patterns of Coexistence of Multiple Chronic Conditions among Chinese Elderly [J]. Chinese General Practice, 2023, 26(29): 3608-3615. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||